High Expression of MiR-21 in Triple-negative Breast Cancers Was Correlated with a Poor Prognosis and Promoted Tumor Cell in Vitro Proliferation

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2014 Jun 16

PMID 24930006

Citations 46

Authors

Guizhi Dong

Xiaoling Liang

Deguang Wang

Huiquan Gao

Ling Wang

Lili Wang

Jingjun Liu

Zhaohui Du

Affiliations

Soon will be listed here.

Abstract

The triple-negative breast cancer (TNBC), with a particularly poor prognosis, is increasingly recognized as heterogeneous in molecular signatures. MicroRNA expression profiles have been used for the classification and prognostication of breast cancer, numerous significantly upregulated microRNAs, i.e. miR-21, have been verified oncogenic in non-TNBCs. In present study, we determined the miR-21 levels in TNBC specimens, and TNBC cell levels in vitro, and then identified the role of miR-21 on tumor cell proliferation, apoptosis, and then identified PTEN as the possible target of the microRNA. It was shown that miR-21 expression is upregulated generally, and heterogeneous in TNBC specimens, posing a correlation with poor prognosis for TNBC patients. Further results demonstrated that the upregulated miR-21 promoted the tumor proliferation and inhibited cell apoptosis in vitro. And pro-apoptotic PTEN had been shown being targeted and downregulated. Therefore, our finding emphasized the oncogenic role of miR-21 in TNBC.

Citing Articles

Platelet-derived microvesicles isolated from type-2 diabetes mellitus patients harbour an altered miRNA signature and drive MDA-MB-231 triple-negative breast cancer cell invasion.

Tutuianu A, Anene C, Shelton M, Speirs V, Whitelaw D, Thorpe J PLoS One. 2024; 19(6):e0304870.

PMID: 38900754 PMC: 11189239. DOI: 10.1371/journal.pone.0304870.

Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches.

Pastena P, Perera H, Martinino A, Kartsonis W, Giovinazzo F Int J Mol Sci. 2024; 25(5).

PMID: 38473804 PMC: 10931553. DOI: 10.3390/ijms25052559.

ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!.

Chamandi G, El-Hajjar L, Kurdi A, Le Bras M, Nasr R, Lehmann-Che J Biomedicines. 2023; 11(8).

PMID: 37626796 PMC: 10452617. DOI: 10.3390/biomedicines11082300.

Cascade Amplified Plasmonics Molecular Biosensor for Sensitive Detection of Disease Biomarkers.

Wang H, Vo-Dinh T Biosensors (Basel). 2023; 13(8).

PMID: 37622860 PMC: 10452163. DOI: 10.3390/bios13080774.

Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy.

Balahura Stamat L, Dinescu S, Costache M Int J Mol Sci. 2023; 24(4).

PMID: 36834660 PMC: 9963301. DOI: 10.3390/ijms24043245.

References

Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C . Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009; 9(1):29-33. DOI: 10.3816/CBC.2009.n.005. View

Jay C, Nemunaitis J, Chen P, Fulgham P, Tong A . miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007; 26(5):293-300. DOI: 10.1089/dna.2006.0554. View

Kim S, Li Z, Moore P, Monaghan A, Chang Y, Nichols M . A sensitive non-radioactive northern blot method to detect small RNAs. Nucleic Acids Res. 2010; 38(7):e98. PMC: 2853138. DOI: 10.1093/nar/gkp1235. View

Corcoran C, Friel A, Duffy M, Crown J, ODriscoll L . Intracellular and extracellular microRNAs in breast cancer. Clin Chem. 2010; 57(1):18-32. DOI: 10.1373/clinchem.2010.150730. View

Gelmon K, Dent R, Mackey J, Laing K, McLeod D, Verma S . Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol. 2012; 23(9):2223-2234. DOI: 10.1093/annonc/mds067. View

Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob S, Patel T . MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007; 133(2):647-58. PMC: 4285346. DOI: 10.1053/j.gastro.2007.05.022. View

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View

Zhu Y, Hoell P, Ahlemeyer B, Krieglstein J . PTEN: a crucial mediator of mitochondria-dependent apoptosis. Apoptosis. 2006; 11(2):197-207. DOI: 10.1007/s10495-006-3714-5. View

Prat A, Perou C . Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2010; 5(1):5-23. PMC: 5528267. DOI: 10.1016/j.molonc.2010.11.003. View

10.

Weng L, Brown J, Eng C . PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet. 2001; 10(3):237-42. DOI: 10.1093/hmg/10.3.237. View

11.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

12.

Putti T, Abd El-Rehim D, Rakha E, Paish C, Lee A, Pinder S . Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2004; 18(1):26-35. DOI: 10.1038/modpathol.3800255. View

13.

Volinia S, Galasso M, Sana M, Wise T, Palatini J, Huebner K . Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A. 2012; 109(8):3024-9. PMC: 3286983. DOI: 10.1073/pnas.1200010109. View

14.

Thomssen C, Pierga J, Pritchard K, Biganzoli L, Cortes-Funes H, Petrakova K . First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology. 2012; 82(4):218-27. DOI: 10.1159/000336892. View

15.

Kreike B, Van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H . Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9(5):R65. PMC: 2242660. DOI: 10.1186/bcr1771. View

16.

Reinhart B, Slack F, Basson M, Pasquinelli A, Bettinger J, Rougvie A . The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403(6772):901-6. DOI: 10.1038/35002607. View

17.

Mulrane L, Madden S, Brennan D, Gremel G, McGee S, McNally S . miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro. Clin Cancer Res. 2012; 18(24):6702-13. DOI: 10.1158/1078-0432.CCR-12-1420. View

18.

Zheng S, Guo G, Zhang W, Huang G, Hu X, Zhu J . Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis. Oncol Rep. 2012; 27(4):1149-55. PMC: 3583512. DOI: 10.3892/or.2012.1634. View

19.

Brennecke J, Hipfner D, Stark A, Russell R, Cohen S . bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 2003; 113(1):25-36. DOI: 10.1016/s0092-8674(03)00231-9. View

20.

Yu S, Chen H, Yang P, Chen J . Unique MicroRNA signature and clinical outcome of cancers. DNA Cell Biol. 2007; 26(5):283-92. DOI: 10.1089/dna.2006.0555. View